VivoSeq
Gastroenterology

Crohn's Disease (CD)

0

Pipeline Programs↗

1

Active Trials↗

4

Companies Involved↗

Crohn's Disease (CD) is an early-stage landscape with 0 programs across 4 companies. The most active players are UCB, Takeda, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

23/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalJohnson & Johnson logo

Johnson & Johnson

0 programs

PreclinicalTanabe Pharma Corporation logo

Tanabe Pharma Corporation

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Completed6 · 46%
Terminated3 · 23%
Unknown status2 · 15%
No longer available1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal Crohn's Disease: A Phase II Randomized Trial
Recruiting·TThe Cleveland Clinic·Preclinical·NCT07680283·44 enrolled
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)
Completed·Takeda logoTakeda·Phase 3·NCT02611817·644 enrolled
Triple Combination Therapy in High Risk Crohn's Disease (CD)
Completed·Takeda logoTakeda·Phase 4·NCT02764762·55 enrolled
Efficacy and Safety of Increased Dose of TA-650 (Infliximab) in Patients With Crohn's Disease (CD)
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 3·NCT00805766·39 enrolled
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
Completed·—·Phase 3·NCT00300118·311 enrolled
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
Completed·UCB logoUCB·Phase 3·NCT00160524·596 enrolled
Mucosal Healing Study in Crohn's Disease (CD)
Completed·UCB logoUCB·Phase 3·NCT00297648·89 enrolled
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
Terminated·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT04186247·13 enrolled
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
Terminated·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT01190839·297 enrolled
The Effect of Adalimumab on the Bone Microstructure in Crohn's Disease (CD) Patients
Terminated·—·N/A·NCT01012570·34 enrolled
Adalimumab for the Management of Post-operative Crohn's Disease (CD)
Unknown status·TTel-Aviv Sourasky Medical Center·Phase 3·NCT01629628·100 enrolled
The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)
Unknown status·JJinling Hospital, China·N/A·NCT01823042·100 enrolled
CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)
No longer available·UCB logoUCB·N/A·NCT03559660

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)